Lotus Pharmaceutical Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Lotus Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 22.3% bzw. 12.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22.8% betragen.
Wichtige Informationen
22.3%
Wachstumsrate der Gewinne
21.7%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 58.7% |
| Wachstumsrate der Einnahmen | 12.4% |
| Zukünftige Eigenkapitalrendite | 22.8% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 18 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 16
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next
Aug 14Recent updates
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 16Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem
Nov 14Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden
Oct 23Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next
Aug 14Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)
Jul 18Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?
Apr 24Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price
Apr 09Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals
Mar 22These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively
Apr 04Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 09Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?
Feb 11
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?
Jan 21Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?
Dec 31I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease
Dec 10Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next
Nov 19Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 22,243 | 6,565 | N/A | 9,330 | 1 |
| 12/31/2025 | 21,271 | 6,202 | 6,315 | 6,747 | 5 |
| 12/31/2024 | 18,464 | 4,789 | 4,772 | 6,191 | 5 |
| 9/30/2024 | 17,594 | 4,333 | 3,293 | 4,622 | N/A |
| 6/30/2024 | 16,933 | 4,014 | 2,455 | 4,071 | N/A |
| 3/31/2024 | 16,632 | 3,948 | 1,717 | 3,325 | N/A |
| 12/31/2023 | 16,958 | 4,106 | -1,661 | 1,614 | N/A |
| 9/30/2023 | 16,710 | 3,873 | -918 | 3,440 | N/A |
| 6/30/2023 | 17,527 | 4,707 | -1,211 | 2,974 | N/A |
| 3/31/2023 | 15,995 | 3,769 | -894 | 3,251 | N/A |
| 12/31/2022 | 14,633 | 3,021 | 650 | 3,719 | N/A |
| 9/30/2022 | 14,264 | 3,105 | 181 | 2,198 | N/A |
| 6/30/2022 | 11,932 | 1,374 | -227 | 2,012 | N/A |
| 3/31/2022 | 12,486 | 1,401 | -1,892 | 496 | N/A |
| 12/31/2021 | 12,649 | 1,403 | -1,496 | 120 | N/A |
| 9/30/2021 | 12,977 | 1,470 | -1,029 | 421 | N/A |
| 6/30/2021 | 12,806 | 1,400 | -1,182 | 26 | N/A |
| 3/31/2021 | 12,019 | 1,344 | 371 | 1,447 | N/A |
| 12/31/2020 | 10,729 | 1,027 | -49 | 1,949 | N/A |
| 9/30/2020 | 10,802 | 848 | -552 | 1,619 | N/A |
| 6/30/2020 | 9,933 | 769 | -863 | 1,116 | N/A |
| 3/31/2020 | 9,307 | 519 | -980 | 905 | N/A |
| 12/31/2019 | 9,611 | 663 | -686 | 420 | N/A |
| 9/30/2019 | 8,130 | 596 | -523 | 266 | N/A |
| 6/30/2019 | 7,693 | 463 | 1 | 691 | N/A |
| 3/31/2019 | 7,278 | 359 | 39 | 720 | N/A |
| 12/31/2018 | 6,429 | 99 | 403 | 797 | N/A |
| 9/30/2018 | 6,537 | 38 | 401 | 774 | N/A |
| 6/30/2018 | 6,535 | 19 | N/A | 657 | N/A |
| 3/31/2018 | 6,477 | 110 | N/A | 623 | N/A |
| 12/31/2017 | 6,424 | 22 | N/A | 591 | N/A |
| 9/30/2017 | 6,072 | -171 | N/A | 696 | N/A |
| 6/30/2017 | 5,897 | -252 | N/A | 965 | N/A |
| 3/31/2017 | 5,913 | -270 | N/A | 1,186 | N/A |
| 12/31/2016 | 5,903 | -134 | N/A | 1,233 | N/A |
| 9/30/2016 | 5,896 | 78 | N/A | 1,490 | N/A |
| 6/30/2016 | 5,910 | 126 | N/A | 1,378 | N/A |
| 3/31/2016 | 5,653 | 198 | N/A | 1,223 | N/A |
| 12/31/2015 | 5,522 | 104 | N/A | 1,078 | N/A |
| 9/30/2015 | 4,712 | -102 | N/A | 436 | N/A |
| 6/30/2015 | 3,879 | -204 | N/A | -531 | N/A |
| 3/31/2015 | 3,125 | -312 | N/A | -886 | N/A |
| 12/31/2014 | 2,310 | -442 | N/A | -1,032 | N/A |
| 9/30/2014 | 2,201 | -307 | N/A | -1,310 | N/A |
| 6/30/2014 | 2,152 | -269 | N/A | -503 | N/A |
| 3/31/2014 | 2,411 | -330 | N/A | -379 | N/A |
| 12/31/2013 | 2,092 | -143 | N/A | -388 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1795Das prognostizierte Gewinnwachstum (22.3% pro Jahr) liegt über der Sparquote (1.1%).
Ertrag vs. Markt: 1795Die Erträge des Unternehmens (22.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (19.5% pro Jahr).
Hohe Wachstumserträge: 1795Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: 1795Die Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt TW (12.6% pro Jahr).
Hohe Wachstumseinnahmen: 1795Die Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1795Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22.8%)